NCT04986020

Brief Summary

The study will use routine computer tomography (CT), magnetic resonance spectroscopy (MRI) and nuclear medicine (NM) brain imaging data to produce new diagnostic tests for the onset of Parkinson's disease. This will enable hopefully earlier diagnosis than is currently possible. This will entail the analysis of anonymised CT/MRI/NM brain images collected prior to the point when these subjects were diagnosed with PD.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2021

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2021

Completed
11 days until next milestone

Study Start

First participant enrolled

August 1, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 2, 2021

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

August 2, 2021

Status Verified

July 1, 2021

Enrollment Period

2.9 years

First QC Date

July 21, 2021

Last Update Submit

July 21, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • The presence of novel putative biomarkers of future PD development as defined by a deep-learning method

    3 years

Study Arms (2)

Parkinson disease

Participants with a clinical diagnosis of Parkinson's disease

Diagnostic Test: MRI

Control

Controls

Diagnostic Test: MRI

Interventions

MRIDIAGNOSTIC_TEST

Identification of novel biomarkers from MRI

ControlParkinson disease

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants drawn from the catchment areas of participating healthcare organisations

You may qualify if:

  • \- A clinical diagnosis of Parkinson's

You may not qualify if:

  • \- No clinical diagnosis of Parkinson's

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Central Study Contacts

Stephen Mullin, MRCP. PhD.

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Lecturer in Neurology

Study Record Dates

First Submitted

July 21, 2021

First Posted

August 2, 2021

Study Start

August 1, 2021

Primary Completion

July 1, 2024

Study Completion

July 1, 2024

Last Updated

August 2, 2021

Record last verified: 2021-07